Neuromyelitis optica (NMO), or NMO syndrome, is a demyelinating disease of the central nervous system characterized by inflammation and damage to the myelin sheath of the optic nerves and spinal cord. The condition can cause severe neurological deficits, including vision loss and paralysis, but its clinical manifestations can vary greatly. Neuromyelitis optica is classified as an autoimmune disease, in which the body's own antibodies attack the tissues of the nervous system. Importantly, NMO typically manifests in episodes of contamination and remission, with repeated attacks possibly leading to increasing functional deficits.
History of the disease and interesting historical facts
The history of neuromyelitis optica began in the late 19th century, when the disease was first described in medical literature. In 1894, German neurologist K.F. Friedrich identified the combination of optic neuritis and myelitis, describing the clinical characteristics of this syndrome. Since the 2000s, thanks to modern research methods, it has become clear that NMO is a separate clinical syndrome, different from multiple sclerosis (MS). In 2004, the AQP4 antibody was identified, which greatly changed the understanding of the pathogenesis of NMO. This discovery allowed not only to improve diagnostics, but also to open up new avenues for the treatment of the disease.
Epidemiology
Epidemiological studies show that the prevalence of neuromyelitis optica varies by geographic region and ethnic group. Most cases occur in women aged 20 to 40 years. According to statistics, NMO is more common in Asians and blacks, while the prevalence of this disease is significantly lower in the white population. In the United States, the incidence is 4.4 per 100,000 people, while in Japan it reaches 10 per 100,000. It should also be noted that incidence data may be unreliable due to underestimation or misdiagnosis.
Genetic predisposition to this disease
There is evidence of a genetic predisposition to neuromyelitis optica. Studies show that certain genes involved in the immune response may increase the risk of developing NMO. In particular, special attention is paid to the genes encoding AQP4 (aquaporins) and HLA-DRB1 (genes of the major histocompatibility complex). In addition, some mutations associated with impaired immune function may also be involved in the pathogenesis of NMO. However, hereditary factors are not yet decisive, and environmental influences remain an important variable.
Risk factors for the development of this disease
Risk factors that contribute to the development of neuromyelitis optica include:
- Gender: The disease is more common in women than in men (ratio 4:1).
- Ethnic factor: African Americans and people of some Asian descent are at increased risk.
- Immune diseases: Coexisting autoimmune conditions may increase the risk, such as systemic lupus erythematosus or Sjogren's syndrome.
- Viral infections: Some viruses, such as the Epstein-Barr virus, may predispose you to developing NMO.
- Genetic predisposition: Having certain genes may increase your risk, as mentioned earlier.
Diagnosis of this disease
Diagnosis of neuromyelitis opticus involves several methods that combine clinical, laboratory and radiological studies. The main symptoms of the disease may include:
- Sudden loss of vision, usually in one eye.
- Pain in the eyes, especially when moving.
- Symptoms of spinal cord injury, such as paralysis or sensory disturbances.
- Increased spasticity and bladder dysfunction.
Laboratory tests include blood tests for AQP4 antibodies. Radiological examinations such as MRI are key in diagnosis, showing high signal in the optic nerves and spinal cord. Differential diagnosis includes multiple sclerosis, viral and bacterial meningitis, and other demyelinating diseases.
Treatment
Treatment for neuromyelitis optica is aimed at relieving symptoms and preventing relapses. General treatment includes:
- Steroid therapy to reduce inflammation during flare-ups.
- Immunosuppressants to control chronic inflammation.
- Plasmapheresis to remove antibodies from the blood in severe cases.
Pharmacological treatment may include:
- Methylprednisolone - a short course of high doses to relieve an exacerbation.
- Azathioprine and mycophenolate mofetil are immunosuppressants used to prevent new attacks.
- Toclizumab is a monoclonal antibody for the treatment of NMO in patients with positive AQP4 antibodies.
Surgical treatment may be considered if it is necessary to remove the affected areas of the nerve structures. In addition, physical therapy and rehabilitation are an important part of a comprehensive approach to treating the disease.
List of medications used to treat this disease
- Methylprednisolone
- Azathioprine
- Mycophenolate mofetil
- Toclizumab
- Plasmapheresis
Disease monitoring
Monitoring of neuromyelitis optica involves regular meetings with a neurologist and conducting control research methods. Control stages should include:
- Assessment of clinical symptoms and their progression.
- Routine MRI scans to monitor changes in tissue.
- Laboratory tests to monitor side effects from therapy.
The prognosis for patients with NMO depends on timely diagnosis and treatment. Complications may include severe impairment of vision and motor function, which significantly affects the quality of life of such patients.
Age-related features of the disease
Neuromyelitis optica can affect a variety of age groups, but is most commonly diagnosed in young women. Children may have more severe disease, while older patients often have milder episodes. It is important to consider differences in response to therapy with age, which may require individualized treatment and monitoring.
Questions and Answers
- What is neuromyelitis optica? Neuromyelitis optica is a disease associated with inflammation and demyelination of the spinal cord and optic nerves, resulting in vision loss and neurological impairment.
- What are the main symptoms of NMO? The main symptoms include sudden vision loss, eye pain, paralysis and sensory disturbances, and spasticity.
- How is NMO diagnosed? Diagnosis includes clinical evaluation, AQP4 antibody testing, MRI, and differential diagnosis to exclude other diseases.
- How is NMO treated? Treatment includes steroids, immunosuppressants, and plasmapheresis, as well as rehabilitation to improve functioning.
- What is the prognosis for patients with NMO? The prognosis depends on the timeliness of diagnosis and treatment; with adequate therapy, partial or complete remission is possible, but complications may also arise.
